Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02614703
Recruitment Status : Terminated (Sample was under-powered)
First Posted : November 25, 2015
Results First Posted : August 26, 2019
Last Update Posted : August 26, 2019
Sponsor:
Information provided by (Responsible Party):
Ingrid Chacon, MD, Doctors Hospital at Renaissance

Brief Summary:
Neoplasia in Barrett's esophagus could be missed during routine random biopsies. We propose a study using chromoendoscopy with Acetic Acid to increase the yield of biopsies in detecting neoplasia.

Condition or disease Intervention/treatment Phase
Barrett's Esophagus Drug: Chromoendoscopy using Acetic Acid 2.5% Other: Standard random esophageal biopsies Phase 2 Phase 3

Detailed Description:

Neoplasia in Barrett's esophagus is often focal and can be missed by nontargeted biopsies alone. In recent years, various advanced endoscopic techniques have been utilized, but with varying success rates. Narrow-band imaging, trimodal imaging, spectral imaging and i-scan are technologies that are manufacturer dependent with limited varying success rates and have financial implications. At our institution, narrow band imaging is routinely utilized as a diagnostic tool for detecting Barrett's esophagus. Acetic acid is a commonly available dye that has been used in the detection of neoplasia in Barrett's esophagus.

This study is aimed to prove the effectiveness of acetic acid chromoendoscopy in our Barrett's esophagus surveillance population. The goal is to compare the neoplasia yield of acetic acid chromoendoscopy with that of standardized random biopsy protocol. The sensitivity and specificity for neoplasia detection by these two methods will also be analyzed.

Investigators plan to conduct this prospective randomized study for a period of one and a half years (beginning August 1, 2015, ending February 29, 2016). Based on data from 2014, we anticipate to enroll approximately 185 patients. All gastroenterologists (with privileges at Doctors Hospital at Renaissance) will participate in this study. Patients will be randomized to either acetic acid chromoendoscopy or current standard of care (standardized random biopsy protocol utilizing narrow band imaging). Random biopsies from both protocols and targeted biopsies (if identified) will be obtained and submitted to pathology department. These will be reviewed independently by two pathologists. Any discordant results will be reviewed by an outside expert pathologist. Statistical data analysis will be performed utilizing Datadesk XL software.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: "Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance is Superior to the Standardized Random Biopsy Protocol in Detecting Neoplasia: A Prospective Randomized Study"
Actual Study Start Date : March 10, 2017
Actual Primary Completion Date : July 30, 2018
Actual Study Completion Date : July 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Experimental: Chromoendoscopy using Acetic Acid 2.5%
Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
Drug: Chromoendoscopy using Acetic Acid 2.5%
Spraying esophageal mucosa during random biopsies for Barrett's esophagus
Other Name: chromoendoscopy using ethanoic acid 2.5%

Active Comparator: Standard random esophageal biopsies
Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
Other: Standard random esophageal biopsies
Random esophageal biopsies performed as per protocol




Primary Outcome Measures :
  1. Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies. [ Time Frame: 142 seconds ]
    Spray of Acetic Acid into the esophageal mucosa during routine esophageal biopsies for Barrett's esophagus surveillance increases the yield of neoplasia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients 18 years and older
  • Previous diagnosis of Barrett's esophagus, confirmed by pathology.

Exclusion Criteria:

  • Patients diagnosed with any level of dysplasia on previous esophageal biopsies.
  • Patients who had esophageal therapy with Halo radiofrequency ablation in the past, or esophagectomy.
  • History of allergy to Acetic Acid
  • History of esophageal dysplasia or cancer
  • Esophageal ulcerations
  • Esophageal Candida
  • Esophageal Varices
  • Patients with active esophagitis
  • Patients who cannot provide a valid consent
  • Patients who are currently pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02614703


Locations
Layout table for location information
United States, Texas
Doctors Hospital at Renaissance/Endoscopy Department
Edinburg, Texas, United States, 78539
Sponsors and Collaborators
Doctors Hospital at Renaissance
Investigators
Layout table for investigator information
Principal Investigator: Ingrid M Chacon, MD Doctor's Hospital at Renaissance
  Study Documents (Full-Text)

Documents provided by Ingrid Chacon, MD, Doctors Hospital at Renaissance:

Publications:
Layout table for additonal information
Responsible Party: Ingrid Chacon, MD, Gastroenterology Specialist, Doctors Hospital at Renaissance
ClinicalTrials.gov Identifier: NCT02614703     History of Changes
Other Study ID Numbers: 0000001
First Posted: November 25, 2015    Key Record Dates
Results First Posted: August 26, 2019
Last Update Posted: August 26, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make individual data available unless otherwise asked for safety reason.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ingrid Chacon, MD, Doctors Hospital at Renaissance:
Barrett's Esophagus
Acetic Acid Chromoendoscopy
Additional relevant MeSH terms:
Layout table for MeSH terms
Barrett Esophagus
Precancerous Conditions
Neoplasms
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Acetic Acid
Retinol acetate
Anti-Bacterial Agents
Anti-Infective Agents
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Anticarcinogenic Agents
Protective Agents
Antineoplastic Agents